From the Research
CJC-1295 should only be used under medical supervision for legitimate medical conditions, with a typical dosage ranging from 100-300mcg administered via subcutaneous injection 2-3 times weekly. The effects of CJC-1295 include increased muscle mass, reduced body fat, improved recovery, and enhanced sleep quality, as it stimulates the pituitary gland to increase growth hormone production 1. Key points to consider when using CJC-1295 include:
- Side effects may include injection site reactions, water retention, headaches, numbness in extremities, and potential impacts on insulin sensitivity
- CJC-1295 is often combined with other peptides like ipamorelin for synergistic effects
- Users should maintain proper injection technique, store the reconstituted peptide refrigerated, and cycle usage (typically 8-12 weeks on, 4 weeks off) to prevent pituitary desensitization
- This compound works by extending the half-life of natural GHRH through Drug Affinity Complex (DAC) technology, allowing for sustained growth hormone release rather than the sharp peaks seen with other peptides
- It's essential to note that CJC-1295 is not FDA-approved for human use and remains primarily investigational or used off-label, with potential performance-enhancing effects that have led to its inclusion on the WADA Prohibited List 2. Recent studies have focused on the detection of CJC-1295 in various samples, including equine plasma, using techniques such as immuno-polymerase chain reaction (I-PCR) assays 3. However, the primary consideration for medical use should be based on the most recent and highest quality study, which emphasizes the importance of medical supervision and proper usage protocols to minimize risks and maximize benefits 1.